Seqens
FranceWho owns Seqens?
Seqens is a French Pharma company, currently owned by Societe Generale Capital Partenaires since 2021 and 3 other investors. It changed hands in 2016, when Ardian sold.
Hand-verified · updated 2026-04-21
Open JSON · CC-BY
Key facts
- ·Co-held by Merieux Equity Partners, Ardian, Societe Generale Capital Partenaires and Eurazeo since 2016.
- ·4 distinct PE sponsors across ownership cycles.
Ownership history
5 ownership periods · co-invest detected · 1 lender on file
Ardian sold Seqens to Eurazeo and Mérieux Développement in 2016 after 5 years.
More from Nov Sante Actions Non Cotees
Other portfolio companies in the same fund.
More PE-backed in Pharma
Comparable pharma deals from other GPs.
US
SpainQuestions
Who owns Seqens?
Seqens is currently owned by Societe Generale Capital Partenaires, Eurazeo and 2 others, through Nov Sante Actions Non Cotees, since 2021.
When did Societe Generale Capital Partenaires and 3 others acquire Seqens?
Societe Generale Capital Partenaires and 3 others acquired Seqens in 2021.
Who did Seqens sell to?
Ardian sold Seqens to Eurazeo and Mérieux Développement in 2016 (Secondary).
Who has owned Seqens over time?
Seqens has been through 6 private-equity ownership periods: Ardian · via Ardian Buyout Fund V · 2011–2016 · sold to Eurazeo and Mérieux Développement · (Secondary); Merieux Equity Partners · via Mérieux Participations 2 · since 2016; Ardian · via Ardian Co-Investment Fund IV · since 2016; Societe Generale Capital Partenaires · via SGCP Evergreen (balance sheet) · since 2021; CIC Private Debt · via CM-CIC Debt Fund 3 · 2021–2016; Eurazeo · via Nov Sante Actions Non Cotees · since 2021.